6

EXHIBIT 3 Case 1:05-cv-12237-WGY Document 266-4 Filed 01/26/2007 Page 1 of 6 Amgen Inc. v. F. Hoffmann-LaRoche LTD et al Doc. 266 Att. 3 Dockets.Justia.com

Attachment 3 DECLARATION of William G. Gaede, III, In ... · January 10, 2007. We further are producing documents that discuss the factors that affect the price of EPOGEN@ and ARANESP©

Download PDF Report

Upload
others
View
0
Download
0

Embed Size (px)

Citation preview

Page 1: Attachment 3 DECLARATION of William G. Gaede, III, In ... · January 10, 2007. We further are producing documents that discuss the factors that affect the price of EPOGEN@ and ARANESP©

EXHIBIT 3

Case 1:05-cv-12237-WGY Document 266-4 Filed 01/26/2007 Page 1 of 6Amgen Inc. v. F. Hoffmann-LaRoche LTD et al Doc. 266 Att. 3

Dockets.Justia.com

http://dockets.justia.com/docket/court-madce/case_no-1:2005cv12237/case_id-100734/

http://docs.justia.com/cases/federal/district-courts/massachusetts/madce/1:2005cv12237/100734/266/3.html

http://dockets.justia.com/

Page 2: Attachment 3 DECLARATION of William G. Gaede, III, In ... · January 10, 2007. We further are producing documents that discuss the factors that affect the price of EPOGEN@ and ARANESP©

Case 1:05-cv-12237-WGY Document 266-4 Filed 01/26/2007 Page 2 of 6

Page 3: Attachment 3 DECLARATION of William G. Gaede, III, In ... · January 10, 2007. We further are producing documents that discuss the factors that affect the price of EPOGEN@ and ARANESP©

Case 1:05-cv-12237-WGY Document 266-4 Filed 01/26/2007 Page 3 of 6

Page 4: Attachment 3 DECLARATION of William G. Gaede, III, In ... · January 10, 2007. We further are producing documents that discuss the factors that affect the price of EPOGEN@ and ARANESP©

Case 1:05-cv-12237-WGY Document 266-4 Filed 01/26/2007 Page 4 of 6

Page 5: Attachment 3 DECLARATION of William G. Gaede, III, In ... · January 10, 2007. We further are producing documents that discuss the factors that affect the price of EPOGEN@ and ARANESP©

Case 1:05-cv-12237-WGY Document 266-4 Filed 01/26/2007 Page 5 of 6

Page 6: Attachment 3 DECLARATION of William G. Gaede, III, In ... · January 10, 2007. We further are producing documents that discuss the factors that affect the price of EPOGEN@ and ARANESP©

Case 1:05-cv-12237-WGY Document 266-4 Filed 01/26/2007 Page 6 of 6

CENTER FOR DRUG EVALUATION AND RESEARCH · Revised labeling for Epogen and PROCRIT, including an annotated redline package insert, clean package insert, redline Medication Guide,

CENTER FOR DRUG EVALUATION AND RESEARCH · Revised labeling for Epogen and PROCRIT, including an annotated redline package insert, clean package insert, redline Medication Guide,

Documents

Dr. Rhonda Kay Gaede UAHgaede/cpe633/08s_cpe633_chap2.pdf · 1 1 Electrical and Computer Engineering CPE 633 Chapter 2 – Hardware Fault Tolerance Dr. Rhonda Kay Gaede UAH Electrical

Dr. Rhonda Kay Gaede UAHgaede/cpe633/08s_cpe633_chap2.pdf · 1 1 Electrical and Computer Engineering CPE 633 Chapter 2 – Hardware Fault Tolerance Dr. Rhonda Kay Gaede UAH Electrical

Documents

Package leaflet: Information for the user Aranesp 10

Package leaflet: Information for the user Aranesp 10

Documents

Epoetin alfa : Epogen ®; Procrit® ; Retacrit

Epoetin alfa : Epogen ®; Procrit® ; Retacrit

Documents

Darbepoetin alfa (Aranesp ® ) molecular characteristics and basic research

Darbepoetin alfa (Aranesp ® ) molecular characteristics and basic research

Documents

In April, 1993, the Agency approved epoetin alfa (epogen) for

In April, 1993, the Agency approved epoetin alfa (epogen) for

Documents

CP.PHAR.237 Epoetin Alfa (Epogen, Procrit), Epoetin Alfa ... › content › dam › centene...Clinical Policy: Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit) Reference

CP.PHAR.237 Epoetin Alfa (Epogen, Procrit), Epoetin Alfa ... › content › dam › centene...Clinical Policy: Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit) Reference

Documents

Status of ILC Computing Model and Cost Study Akiya Miyamoto Norman Graf Frank Gaede Andre Sailer Marcel Stanitzki Jan Strube 1

Status of ILC Computing Model and Cost Study Akiya Miyamoto Norman Graf Frank Gaede Andre Sailer Marcel Stanitzki Jan Strube 1

Documents

Physician Specialty Overview by Prior Authorization ......3963 HEMATOLOGY Aranesp HEMATINICS & BLOOD CELL STIMULATORS Approval 1 3956 PRESCRIBER SPECIALTY, UNKNOWN Armodafinil CNS

Physician Specialty Overview by Prior Authorization ......3963 HEMATOLOGY Aranesp HEMATINICS & BLOOD CELL STIMULATORS Approval 1 3956 PRESCRIBER SPECIALTY, UNKNOWN Armodafinil CNS

Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION ARANESP ... - …/media/amgen/repositorysites/pi-amgen... · HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information

HIGHLIGHTS OF PRESCRIBING INFORMATION ARANESP ... - …/media/amgen/repositorysites/pi-amgen... · HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information

Documents

Meet Mike - Aranesp

Meet Mike - Aranesp

Documents

An Integrated Facility for Rapid Prototyping Rhonda Kay Gaede, B. Earl Wells

An Integrated Facility for Rapid Prototyping Rhonda Kay Gaede, B. Earl Wells

Documents

Introduction to Xilinx Virtex Field-Programmable Gate Arrays ...gaede/cpe422/05s_cpe422_xilinx.pdfXilinx Virtex Field-Programmable Gate Arrays Devices Dr. Rhonda Kay Gaede Electrical

Introduction to Xilinx Virtex Field-Programmable Gate Arrays ...gaede/cpe422/05s_cpe422_xilinx.pdfXilinx Virtex Field-Programmable Gate Arrays Devices Dr. Rhonda Kay Gaede Electrical

Documents

Aranesp (darbepoetin alfa) For Injection WARNINGS ......Aranesp® (darbepoetin alfa) For Injection WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS,

Aranesp (darbepoetin alfa) For Injection WARNINGS ......Aranesp® (darbepoetin alfa) For Injection WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS,

Documents

USE OF DARBEPOETIN ALFA (ARANESP ) FOR ANEMIA … · 2017-01-20 · J of IMAB. 2017 Jan-Mar;23(1) 1421 USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC

USE OF DARBEPOETIN ALFA (ARANESP ) FOR ANEMIA … · 2017-01-20 · J of IMAB. 2017 Jan-Mar;23(1) 1421 USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC

Documents

COMMERCIALIZING THE FIRST BIOTECH BLOCKBUSTER DRUG PRESENTED BY: FARYN KAPALA OCTOBER 26 TH, 2010 Amgen Inc.’s _______ Epogen 1

COMMERCIALIZING THE FIRST BIOTECH BLOCKBUSTER DRUG PRESENTED BY: FARYN KAPALA OCTOBER 26 TH, 2010 Amgen Inc.’s _______ Epogen 1

Documents

CC-1 Aranesp ® (darbepoetin alfa) Therapy for Oncology Patients Oncologic Drugs Advisory Committee May 4, 2004

CC-1 Aranesp ® (darbepoetin alfa) Therapy for Oncology Patients Oncologic Drugs Advisory Committee May 4, 2004

Documents

Erythropoiesis Stimulating Agents (ESAs): Epogen… · Moda Health Plan, Inc. Medical Necessity Criteria Page 2/16 Other causes of anemia (e.g. hemolysis, bleeding, vitamin deficiency,

Erythropoiesis Stimulating Agents (ESAs): Epogen… · Moda Health Plan, Inc. Medical Necessity Criteria Page 2/16 Other causes of anemia (e.g. hemolysis, bleeding, vitamin deficiency,

Documents

Procrit Patient Information Epogen Patient Information

Procrit Patient Information Epogen Patient Information

Documents

Computing in High Frank Gaede, Summer Student Lecture, DESY, August … · · 2007-08-20Frank Gaede, Summer Student Lecture, DESY, August 16, 2007 2 Introduction The aim of this

Computing in High Frank Gaede, Summer Student Lecture, DESY, August … · · 2007-08-20Frank Gaede, Summer Student Lecture, DESY, August 16, 2007 2 Introduction The aim of this

Documents

There’s More to Aranesp Assessing and Managing Anemia...2019/11/29 · Iron deficiency–absolute 1,4,7,26 Iron deficiency–functional 1,4,7,26,28, Secondary HPT 3,4,7,29 Inadequate

There’s More to Aranesp Assessing and Managing Anemia...2019/11/29 · Iron deficiency–absolute 1,4,7,26 Iron deficiency–functional 1,4,7,26,28, Secondary HPT 3,4,7,29 Inadequate

Documents

Electrical and Computer Engineering UAH ASEE Annual Conference Session 1526 An Integrated Facility for Rapid Prototyping Rhonda Kay Gaede, B. Earl Wells

Electrical and Computer Engineering UAH ASEE Annual Conference Session 1526 An Integrated Facility for Rapid Prototyping Rhonda Kay Gaede, B. Earl Wells

Documents

LCIO A persistency framework and data model for the linear collider CHEP 04, Interlaken Core Software, Wednesday 29.09.2004 Frank Gaede, DESY -IT-

LCIO A persistency framework and data model for the linear collider CHEP 04, Interlaken Core Software, Wednesday 29.09.2004 Frank Gaede, DESY -IT-

Documents

Aranesp - Medicines · • your abdomen, except for the area ... How to inject into the abdomen using Aranesp SureClick ... press - you will hear a "click" - and (2) release the red

Aranesp - Medicines · • your abdomen, except for the area ... How to inject into the abdomen using Aranesp SureClick ... press - you will hear a "click" - and (2) release the red

Documents

Erythropoiesis Stimulating Agents (ESAs): Epogen/Procrit ...Anemia due to CKD – non-dialysis § Adults: 50-100 units/kg intravenously or subcutaneously three times weekly Pediatric

Erythropoiesis Stimulating Agents (ESAs): Epogen/Procrit ...Anemia due to CKD – non-dialysis § Adults: 50-100 units/kg intravenously or subcutaneously three times weekly Pediatric

Documents

Meet James - Aranesp

Meet James - Aranesp

Documents

Erythropoiesis Stimulating Agents (ESAs): Epogen/Procrit® · D61.3 Idiopathic aplastic anemia D61.89 Other specified aplastic anemias and other bone marrow failure syndromes D63.0

Erythropoiesis Stimulating Agents (ESAs): Epogen/Procrit® · D61.3 Idiopathic aplastic anemia D61.89 Other specified aplastic anemias and other bone marrow failure syndromes D63.0

Documents

Chapter 8 - Additional Topics in VHDL Dr. Rhonda Kay Gaede UAH

Chapter 8 - Additional Topics in VHDL Dr. Rhonda Kay Gaede UAH

Documents

Revisiting borehole stresses in anisotropic elastic media ... · analytical versus numerical solutions Karpﬁnger, F., Prioul, R. Schlumberger-Doll Research, Cambridge, MA, USA Gaede,

Revisiting borehole stresses in anisotropic elastic media ... · analytical versus numerical solutions Karpﬁnger, F., Prioul, R. Schlumberger-Doll Research, Cambridge, MA, USA Gaede,

Documents

LCIO A persistency framework for LC detector simulation studies Frank Gaede, DESY, IT Linear Collider Simulation Workshop SLAC May 19-22 2003

LCIO A persistency framework for LC detector simulation studies Frank Gaede, DESY, IT Linear Collider Simulation Workshop SLAC May 19-22 2003

Documents